Clinical Trials Logo

Clinical Trial Summary

This is a follow-up study of patients, treated with one daily dose of Zomacton or one daily dose of Genotropin in the previously completed FE 999905 CS07 trial, who had presence of anti-hGH antibodies at any post-dosing visit during the 12-month treatment period. No investigational medicinal product will be administered in connection with this follow-up study. Eligible patients will attend one visit in this follow-up study.


Clinical Trial Description

n/a


Study Design

Endpoint Classification: Pharmacodynamics Study


Related Conditions & MeSH terms


NCT number NCT02173821
Study type Interventional
Source Ferring Pharmaceuticals
Contact
Status Completed
Phase Phase 3
Start date October 2014
Completion date April 2015

See also
  Status Clinical Trial Phase
Completed NCT01419249 - First Year Growth Response Associated Genetic Markers Validation Phase IV Open-label Study in Growth Hormone Deficient and Turner Syndrome Pre-pubertal Children: the PREDICT Pharmacogenetics Validation Study Phase 4
Completed NCT03223025 - Comparing Efficacy and Safety of CinnaGen Biosimilar Growth Hormone (CinnaTropin®) Versus Nordilet in Children With Idiopathic Growth Hormone Deficiency Phase 3